Medicine Matters diabetes

Owing to the COVID-19 pandemic, the 80th ADA Scientific Sessions was an entirely online event. In this podcast, editorial board members Lori Berard, John Wilding, and Sanjay Kalra reflect on this novel format and discuss their scientific highlights.

Find more on Medicine Matters diabetes

Following the wealth of artificial pancreas research presented at this year’s ADA Scientific Sessions, Rayhan Lal (Stanford University, California, USA) reflects on the current status of the field, and suggests where researchers and manufacturers should now be placing their focus for the greatest benefit of people with diabetes.

Find more on Medicine Matters diabetes

Neil Skolnik, Professor of Family and Community Medicine at Sidney Kimmel Medical College in Philadelphia, Pennysylvania, USA, gives his view and outlines key considerations for the use of this new medication as part of a shared decision-making process with people who have type 2 diabetes.

For more of the latest news and insights on diabetes medications, visit: https://bit.ly/MMd_medications

The first author on the American Diabetes Association's 2019 consensus on nutrition therapy for adults with diabetes or prediabetes talks through the update and what it means for educators, practitioners and patients.

The full consensus document is available from Diabetes Care.

Find more on Medicine Matters diabetes

Medical sociologist Ashby Walker, from the University of Florida in Gainesville, talks about a mentoring scheme pairing college students and teenagers who have type 1 diabetes - to the benefit of both.

Find more on Medicine Matters diabetes

Listen to our clinical advisors discussing their EASD 2019 highlights, including new treatment options for children and older adults with type 2 diabetes, the complexities surrounding hypoglycemia prevention, and the implications of the VERIFY trial.

Find more on Medicine Matter diabetes

More from EASD 2019

How will the findings of the REWIND trial and the DECLARE-TIMI 58 renal outcomes analysis affect treatment decisions for high-risk diabetes patients without overt cardiovascular disease? medwireNews asks Kamlesh Khunti.

Find more on Medicine Matters diabetes

Andrew Frankel, Consultant Physician and Nephrologist at Imperial College Healthcare NHS Trust, tells medwireNews about the rationale and key findings of the CREDENCE trial, and discusses the potential benefits of SGLT2 inhibitors beyond type 2 diabetes.

Find more on Medicine Matters diabetes

This content was originally published on Medicine Matters diabetes (https://diabetes.medicinematters.com) on April 17, 2019.

Editorial Board member Lori Berard discusses how to meet and overcome the challenges that follow the initial insulin prescription in patients with type 2 diabetes.

Find more on Medicine Matters diabetes

This content was originally published on Medicine Matters diabetes (https://diabetes.medicinematters.com) on August 1, 2018.

Board members John Wilding and Pamela Dyson talk about the fresh approach taken to the latest update of the Diabetes UK nutrition guidelines.

Find more on Medicine Matters diabetes

This content was originally published on Medicine Matters diabetes (https://diabetes.medicinematters.com) on March 19, 2018.